Principal Investigator
Jonathan Trent
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20250925
Clinical Trial Summary
A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) after Imatinib Therapy (StrateGIST 3)
Phase
Phase III
Funding Agency/Sponsor
Industrial
Disease
Bone and Soft Tissue Cancers
Contact Information
Phone Number
305-243-2647